Page 346 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
program of the
ERSPC. All
men
retrospectively
met the
following
criteria: clinical
stage T1c or
T2, PSA ≤15
ng/mL, and
Gleason score
<8. The choice
of initiating and
continuing an
AS was patient
desire and/or
physician
advice. 150
ERSPC-screening
protocol: Men
aged 50–75 yr
with PSA
measurements
(threshold 3.0
or 4.0 ng/ml),
and/or TRUS,
and/or DRE, at
2- or 4-yr
intervals.
Abnormal
findings lead to
sextant prostate
biopsies, the
Finnish centers
have changed
to 10 or 12
biopsy cores.
Prostatic
volume is

C-91